All issues > Volume 34(8); 1991

Original Article

J Korean Pediatr Soc. 1991;34(8):1110-1115. Published online August 31, 1991.

Clinical effects of recombinant Korean growth hormone (LBD-003).

Duk Hi Kim¹

¹Department of Pediatrics, Yonsei University College of Medicine, Seoul, Korea

Received: June 4, 1991;  Accepted: July 8, 1991.

Abstract

LBD-003, methionyl GH, has been produced recently in the yeast by the use of recombinant method. The clinical efficacy and immunogenecity of LBD-003 were studied in 20 patients with naive GH deficiency. The subjects of this study were aged 5.1—13.9 years and received GH 1.5IU/kg thrice weekly for 1 year. During treatment, height, body weight & bone age were checked. Blood count, chemistry amd thyroid hormonal concentrations were checked, measurement of IGF-1 was done before and every 6 month and assay of antibody was performed before, 6 month and 12 month treatment. The height veloity was increased 8.55±2.28 cm/yr at 6 month & 7.22±1.46 cm/yr from 3.20±l. 21 cm/yr. The ratio of height age and bone age was 1.34 at 6 month and 1.31 at 1 year of therapy. The plasma IGF-1 levels rose significantly during treatment. No antibody against LBD-003 was observed in all patients. Thus, LBD-003 is very effective in stimulating linear growth in hGH deficiency.

Keywords :Short Stature;Growth Hormone Therapy